ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
A 2-Biomarker Model Augments Clinical Prediction of Mortality in Melioidosis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- Review
- Targeting inflammasome, IL-1β, and coagulation in melioidosis.Frontiers in microbiology · 2026Review
- Circulating Interleukin-6 as a Prognostic Biomarker for Mortality in Melioidosis: A Systematic Review and Meta-Analysis.Diseases (Basel, Switzerland) · 2025Review
- Proteomic-based identification of novel EV-derived protein antibodies biomarkers for melioidosis diagnosis.PLoS neglected tropical diseases · 2025Article
- Biological subphenotypes in patients hospitalized with suspected infection in Thailand: a secondary analysis of a prospective observational study.The Lancet regional health. Southeast Asia · 2025Article
- Article
- Immune responses following DNA vaccination by needle-free injection againstFrontiers in immunology · 2025Article
- Dysfunctional host cellular immune responses are associated with mortality in melioidosis.Emerging microbes & infections · 2024Article
- Article
- Clinical Prediction Rules for In-Hospital Mortality Outcome in Melioidosis Patients.Tropical medicine and infectious disease · 2024Article
- Plasma Metabolomics Reveals Distinct Biological and Diagnostic Signatures for Melioidosis.American journal of respiratory and critical care medicine · 2024Article
- IL-1R2-based biomarker models predict melioidosis mortality independent of clinical data.Frontiers in medicine · 2023Article
- [Establishment of a nomogram model for the early diagnosis of childhood sepsis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- Evaluation of two different vaccine platforms for immunization against melioidosis and glanders.Frontiers in microbiology · 2022Article
- Blood transcriptomics to characterize key biological pathways and identify biomarkers for predicting mortality in melioidosis.Emerging microbes & infections · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundMelioidosis, infection caused by Burkholderia pseudomallei, is a common cause of sepsis with high associated mortality in Southeast Asia. Identification of patients at high likelihood of clinical deterioration is important for guiding decisions about resource allocation and management. We sought to develop a biomarker-based model for 28-day mortality prediction in melioidosis.
methodsIn a derivation set (N = 113) of prospectively enrolled, hospitalized Thai patients with melioidosis, we measured concentrations of interferon-γ, interleukin-1β, interleukin-6, interleukin-8, interleukin-10, tumor necrosis factor-ɑ, granulocyte-colony stimulating factor, and interleukin-17A. We used least absolute shrinkage and selection operator (LASSO) regression to identify a subset of predictive biomarkers and performed logistic regression and receiver operating characteristic curve analysis to evaluate biomarker-based prediction of 28-day mortality compared with clinical variables. We repeated select analyses in an internal validation set (N = 78) and in a prospectively enrolled external validation set (N = 161) of hospitalized adults with melioidosis.
resultsAll 8 cytokines were positively associated with 28-day mortality. Of these, interleukin-6 and interleukin-8 were selected by LASSO regression. A model consisting of interleukin-6, interleukin-8, and clinical variables significantly improved 28-day mortality prediction over a model of only clinical variables [AUC (95% confidence interval [CI]): 0.86 (.79-.92) vs 0.78 (.69-.87); P = .01]. In both the internal validation set (0.91 [0.84-0.97]) and the external validation set (0.81 [0.74-0.88]), the combined model including biomarkers significantly improved 28-day mortality prediction over a model limited to clinical variables.
conclusionsA 2-biomarker model augments clinical prediction of 28-day mortality in melioidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.